|
C16ORF72 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 3.08642000845794E-13 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.98685512486918E-12 |
| Normal-vs-Stage2 |
3.45300454895892E-11 |
| Normal-vs-Stage3 |
8.24895707296491E-14 |
| Normal-vs-Stage4 |
1.62858615482264E-12 |
| Stage1-vs-Stage2 |
7.513600E-01 |
| Stage1-vs-Stage3 |
1.038240E-01 |
| Stage1-vs-Stage4 |
9.759900E-03 |
| Stage2-vs-Stage3 |
4.193800E-01 |
| Stage2-vs-Stage4 |
6.220300E-02 |
| Stage3-vs-Stage4 |
2.332800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
4.404254738688E-13 |
| Normal-vs-AfricanAmerican |
2.52430000002857E-06 |
| Normal-vs-Asian |
2.69284594622832E-12 |
| Caucasian-vs-AfricanAmerican |
3.582600E-01 |
| Caucasian-vs-Asian |
6.905000E-01 |
| AfricanAmerican-vs-Asian |
2.774000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.72095671047146E-12 |
| Normal-vs-Female |
2.24065210829849E-12 |
| Male-vs-Female |
3.017200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
5.64126523272535E-12 |
| Normal-vs-Age(41-60Yrs) |
1.82631687550838E-12 |
| Normal-vs-Age(61-80Yrs) |
3.06421554796543E-14 |
| Normal-vs-Age(81-100Yrs) |
1.060770E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.404600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
5.529600E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
9.160600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.536400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.931800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.427000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
4.157200E-03 |
| Classical-VS-Follicular |
9.983800E-02 |
| Classical-VS-Other |
3.310800E-01 |
| Classical-VS-Normal |
2.7113977729698E-11 |
| Tall-VS-Follicular |
6.922400E-02 |
| Tall-VS-Other |
5.852200E-01 |
| Tall-VS-Normal |
2.54241072639161E-14 |
| Follicular-VS-Other |
7.073000E-01 |
| Follicular-VS-Normal |
3.57902596448412E-12 |
| Other-VS-Normal |
4.001200E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.96065386148803E-13 |
| Normal-vs-N1 |
1.63513647066793E-12 |
| N0-vs-N1 |
5.085700E-02 |
|
|
